#COVID19 cases in the US reported by @CDCGov have continued their week-after-week exponential decline that began in mid-April. This is exceptionally welcome news, although I'm now watching closely for variants driving sub-epidemics despite overall cases falling. 1/10
If we look at state-level cases with a log-axis we can see exponential growth and then exponential decline visible as straight lines on the log plot. Some states have had recent precipitous declines (NY, MA, MI), while others have been more stable (WA, CO, OR). 2/10
Using genomic data shared to @GISAID, we can plot frequency of different variant lineages through time and across states to get a sense of competitive dynamics. Here, I'm plotting lineage frequency on a logit axis, so that logistic growth is visible as a straight-line fit. 3/10
Relative fitness becomes more clear as variants are placed in direct competition. B.1.1.7 and B.1.526 had been increasing rapidly in frequency in New York. However, since they reached high frequency they've been in more direct competition and B.1.1.7 has edged out B.1.526. 4/10
I'm now watching Illinois in particular where P.1 is at ~30% frequency and B.1.1.7 is at ~60% frequency to see if P.1 starts to displace B.1.1.7 there. 5/10
Looking across these nine states, the current ranking of logistic growth rate seems to be B.1.617 > P.1 > B.1.1.7 > B.1.526 > B.1.351. 6/10
Although frequencies are useful to assess competitiveness of different variants, we're interested in case counts to assess whether a variant may be driving an epidemic. Here, I'm using genomic data to partition case counts as described previously. 7/10
Doing so with this latest data gives the following picture where it's clear that non-variant viruses have been declining throughout the spring, while variant viruses have been responsible for multiple state-level epidemics (B.1.526 in NY, B.1.1.7 in MI, MD and MN). 8/10
Because the genomic data is necessarily lagged, this is looking back to the beginning of May and the last 3 weeks of declines in cases are not included. However, even here, there are some encouraging trends of absolute growth of P.1 starting to level off. 9/10
B.1.617 is, of course, worrisome and may gain ground quickly on other lineages, although its lack of significant immune escape makes me less worried about large-scale spread in the US. However, there is still a large unvaccinated population in which B.1.617 may drive cases. 10/10
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Currently, the US is reporting about 54k daily cases of COVID-19 (16 per 100k per capita) and the UK is reporting about 4k (6 per 100k). This seems comfortingly low compared to even this summer's BA.5 wave and let alone last winter's BA.1 wave. Figure from @OurWorldInData. 1/16
However, at this point, nearly all infections will be in individuals with prior immunity from vaccination or infection and this combined with a roll back in testing makes it unclear how to interpret current case counts compared to previous time periods. 2/16
We're interested in the case detection rate or the ratio of underlying new infections compared to reported cases. Throughout much of 2020 and 2021, I had a working estimate of 1 infection in ~3.5 getting reported as a case. 3/16
Largely through partial immune escape, lineage BA.5 viruses resulted in sizable epidemics throughout much of the world. However, in most countries these epidemics are now beginning to wind down. What do we expect after BA.5? 1/10
Lineage BA.2.75 (aka 'Centaurus') has been high on watch lists due to sustained increase in frequency in India combined with the presence of multiple mutations to spike protein. We now have enough sampled BA.2.75 viruses from outside India to make some initial conclusions. 2/10
If we look at frequency data we see sustained logistic growth of BA.2.75 in India, Japan, Singapore and the US. Critically, in India it is clearly displacing BA.5. 3/10
Based on the experience in winter 2020/2021, seasonal influence on SARS-CoV-2 transmission is quite clear, but much of the Northern Hemisphere is currently experiencing large summer epidemics driven the spread of evolved BA.5 viruses. 1/11
It's necessarily fraught to try to make predictions of seasonal circulation patterns going forwards, but we can gain some intuition from simple epidemiological models. 2/11
In particular, we can use an SIRS system in which individuals go from Susceptible to Infected to Recovered, and then return to the Susceptible class due to immune waning / antigenic drift of the virus. 3/11
There seems to be a worry that telling people we've exited the "pandemic phase" will lead to further reduced precautions. As always however, I think it's best not to conduct messaging for intended behavioral effect and just try to make scientifically accurate statements. 1/5
Given vaccination and infection, the US and global population now has widespread immunity to SARS-CoV-2 and deaths per-infection are about 10 times lower than they were pre-immunity in 2020 with a ballpark IFR of 0.05% (though this will vary by immunity and age demographics). 2/5
You can see this reduction in mortality rate in looking at projections of deaths from lagged-cases keyed to early case fatality rate. 3/5
The @US_FDA VRBPAC committee will be meeting tomorrow to discuss variant-specific COVID-19 vaccines (fda.gov/advisory-commi…). Based on present observations, I would argue that the most important metric to optimize are titers against BA.4/BA.5 viruses. 1/10
We've seen repeated replacement of SARS-CoV-2 variants during 2022, first of Delta by Omicron BA.1 and then by sub-lineages of Omicron, with BA.2 replacing BA.1 and now with BA.4/BA.5 replacing BA.2. 2/10
Viruses have been evolving to be higher fitness through both increases in intrinsic transmissibility (seen in BA.2 vs BA.1) as well as escape from existing population immunity (seen in Omicron vs Delta as well as BA.4/BA.5 vs BA.2). 3/10
Global monkeypox confirmed and suspected cases compiled by @globaldothealth show initial rapid increase as case-based surveillance comes online, followed by slower continued growth. 1/10
This is data from github.com/globaldothealt… and has had a 7-day smoothing applied and all y-axes are shown on a log scale. 2/10
If we focus on the last 11 days, we can see steady exponential growth in global cases with a ~7.7 day doubling. 3/10